(Q39183442)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

title

Advances and challenges in targeting FGFR signalling in cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

author name string

Nicholas C Turner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

language of work or name

English

0 references

publication date

17 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

page(s)

318-332

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

Identification of a new fibroblast growth factor receptor, FGFR5

6 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR2 gene amplification and clinicopathological features in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Amplification of chromosome 8 genes in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFs, their receptors, and human limb malformations: clinical and molecular correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Transforming fusions of FGFR and TACC genes in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Identification of targetable FGFR gene fusions in diverse cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Transforming acidic coiled-coil proteins (TACCs) in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Pulling it together: The mitotic function of TACC3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Oncogenic FGFR3 gene fusions in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Dysregulated FGF signalling in neoplastic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGF19 promotes progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGF23 promotes prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The involvement of the chromosome 11q13 region in human malignancies: Cyclin D1 and EMS1 are two new candidate oncogenes-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Cyclin D1, EMS1 and 11q13 amplification in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

TGF-β1 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Subtyping of triple-negative breast cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Competition between Grb2 and Plcγ1 for FGFR2 regulates basal phospholipase activity and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Structural and Functional Diversity in the FGf Receptor Multigene Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Structural analysis of the human fibroblast growth factor receptor 4 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Genetic insights into the mechanisms of Fgf signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Spatial and temporal patterns of ERK signaling during mouse embryogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Roles of intracellular fibroblast growth factors in neural development and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The FGF family: biology, pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Metabolic roles of endocrine fibroblast growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Antagonistic feedback loops involving Rau and Sprouty in the Drosophila eye control neuronal and glial differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A combinatorial strategy for treating KRAS-mutant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Biology-driven phase II trials: what is the optimal model for molecular selection?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

Grb-ing receptor activation by the tail

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.8

31 March 2020

Identifiers

DOI

10.1038/NRC.2017.8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28303906%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference